Thiomyristoyl Clinical Trials

Size	Price	Qty
2mg	USD 147
5mg	USD 270

Clinical Trials

Multiple clinical trials are documented evaluating therapeutic applications, including a Phase 4 trial focusing on type 1 diabetes, diabetic nephropathies, albuminuria, hypoxia, and renal and cardiovascular diabetic complications, as well as a Phase 2 trial for opioid use disorder. Sponsored by organizations such as the Steno Diabetes Center Copenhagen, King's College London, the Juvenile Diabetes Research Foundation, Glostrup University Hospital Copenhagen, and Indivior Inc., these clinical trials are currently listed as not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06147232	Not yet recruiting	Nephropathy\|Diabetic Nephropathies\|Diabetes Mellitus Type 1\|Albuminuria\|Diabetic Complications Renal\|Diabetic Complications Cardiovascular\|Hypoxia	Steno Diabetes Center Copenhagen\|Juvenile Diabetes Research Foundation\|King''s College London\|Glostrup University Hospital Copenhagen	2024-08	Phase 4
NCT06384157	Not yet recruiting	Opioid Use Disorder	Indivior Inc.	2024-05	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Thiomyristoyl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Thiomyristoyl acts as a potent and selective inhibitor of sirtuin 2, binding to the enzyme to block NAD+-dependent deacetylation of downstream protein substrates and regulate key metabolic and cellular stress pathways. This inhibition alters cell survival and transcriptional responses, offering therapeutic potential in modulating renal hypoxia and diabetic nephropathies as well as neurological mechanisms underlying opioid use disorder.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).